INTRODUCTION: We evaluated the currently preferred primary treatment options among German urologists and radio-oncologists if personally diagnosed with localized prostate cancer, taking into consideration the different prognostic risk groups. MATERIALS AND METHODS: A questionnaire was mailed to 3,217 urologists and 598 radio-oncologists. They were asked to choose their preferred primary treatment option if they were personally diagnosed with prostate cancer, taking into consideration the different prognostic risk groups: low risk [Gleason score < or =6, prostate-specific antigen (PSA) < or =10 microg/l, T1c], intermediate risk (Gleason score 7, PSA 11-19 microg/l, T2), and high risk (Gleason score > or =8, PSA> or =20 microg/l, T3). Surgical options were further subdivided according to technique (retropubic, laparoscopic, perineal). RESULTS: The questionnaire return rate was 49% for urologists and 41% for radio-oncologists. The mean age was 48 years (28-86) for urologists and 47 years (29-68) for radio-oncologists. Primary surgical treatment was selected by 62% of urologists for low-risk prostate cancer, 90% for intermediate-risk prostate cancer, and 77% for high-risk prostate cancer. Radiotherapy as a primary treatment option was elected by 71% of radio-oncologists for low-risk prostate cancer, 84% for intermediate-risk prostate cancer, and 89% for high-risk prostate cancer. Retropubic, laparoscopic, and perineal prostatectomy would be chosen by 61%, 28%, and 10% of urologists, respectively, for low-risk prostate cancer; by 70%, 24%, and 6%, respectively, for intermediate-risk prostate cancer, and by 80%, 15%, and 5%, respectively for high-risk prostate cancer. CONCLUSION: Urologists prefer surgery and radio-oncologists radiotherapy for primary treatment of prostate cancer, irrespective of the prognostic risk group. Particularly for high-risk prostate cancer, the majority of radiooncologists would still choose radiotherapy as a primary treatment option. In the age of minimally invasive surgery, radical retropubic prostatectomy is still the preferred surgical treatment option among urologists for any prognostic risk group.
INTRODUCTION: We evaluated the currently preferred primary treatment options among German urologists and radio-oncologists if personally diagnosed with localized prostate cancer, taking into consideration the different prognostic risk groups. MATERIALS AND METHODS: A questionnaire was mailed to 3,217 urologists and 598 radio-oncologists. They were asked to choose their preferred primary treatment option if they were personally diagnosed with prostate cancer, taking into consideration the different prognostic risk groups: low risk [Gleason score < or =6, prostate-specific antigen (PSA) < or =10 microg/l, T1c], intermediate risk (Gleason score 7, PSA 11-19 microg/l, T2), and high risk (Gleason score > or =8, PSA> or =20 microg/l, T3). Surgical options were further subdivided according to technique (retropubic, laparoscopic, perineal). RESULTS: The questionnaire return rate was 49% for urologists and 41% for radio-oncologists. The mean age was 48 years (28-86) for urologists and 47 years (29-68) for radio-oncologists. Primary surgical treatment was selected by 62% of urologists for low-risk prostate cancer, 90% for intermediate-risk prostate cancer, and 77% for high-risk prostate cancer. Radiotherapy as a primary treatment option was elected by 71% of radio-oncologists for low-risk prostate cancer, 84% for intermediate-risk prostate cancer, and 89% for high-risk prostate cancer. Retropubic, laparoscopic, and perineal prostatectomy would be chosen by 61%, 28%, and 10% of urologists, respectively, for low-risk prostate cancer; by 70%, 24%, and 6%, respectively, for intermediate-risk prostate cancer, and by 80%, 15%, and 5%, respectively for high-risk prostate cancer. CONCLUSION: Urologists prefer surgery and radio-oncologists radiotherapy for primary treatment of prostate cancer, irrespective of the prognostic risk group. Particularly for high-risk prostate cancer, the majority of radiooncologists would still choose radiotherapy as a primary treatment option. In the age of minimally invasive surgery, radical retropubic prostatectomy is still the preferred surgical treatment option among urologists for any prognostic risk group.
Authors: Michael P O'leary; Neil H Baum; William W Bohnert; Richard Blizzard; William W Bonney; Thomas P Cooper; Martin K Dineen; William F Gee; E Ann Gormley; Jeffrey M Ignatoff; Daniel A Nachtsheim; M Ray Painter; Raju Thomas; John T Wei Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: D Feldman-Stewart; M D Brundage; C Hayter; P Groome; J C Nickel; H Downes; W J Mackillop Journal: Radiother Oncol Date: 1998-11 Impact factor: 6.280
Authors: Ashutosh Tewari; George Divine; Peter Chang; M Mendel Shemtov; Matthew Milowsky; David Nanus; Mani Menon Journal: J Urol Date: 2007-03 Impact factor: 7.450
Authors: Donna L Berry; William J Ellis; Nancy Fugate Woods; Christina Schwien; Kristin H Mullen; Claire Yang Journal: Urol Oncol Date: 2003 Mar-Apr Impact factor: 3.498
Authors: Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: Scott E Eggener; Peter T Scardino; Peter R Carroll; Michael J Zelefsky; Oliver Sartor; Hedvig Hricak; Thomas M Wheeler; Samson W Fine; John Trachtenberg; Mark A Rubin; Mak Ohori; Kentaro Kuroiwa; Michel Rossignol; Lucien Abenhaim Journal: J Urol Date: 2007-10-15 Impact factor: 7.450
Authors: Andreas Becker; Daniel Seiler; Maciej Kwiatkowski; Luis Alex Kluth; Dietrich Schnell; Markus Graefen; Thorsten Schlomm; Margit Fisch; Franz Recker; Lothar Weissbach; Felix K H Chun Journal: World J Urol Date: 2014-05-13 Impact factor: 4.226
Authors: J Huber; T Peters; A Kessler; A Ihrig; C G Huber; B Hadaschik; S Pahernik; M Hohenfellner Journal: Urologe A Date: 2010-11 Impact factor: 0.639